Tucatinib (TUKYSA) has significant efficacy in brain metastases from HER2-positive breast cancer

The efficacy of Tucatinib (trade name TUKYSA) in HER2-positive breast cancer brain metastases is indeed remarkable, which is mainly due to its high specificity and effectiveness as an oral tyrosine kinase inhibitor (TKI) against HER2.

Tucatinib is an oral TKI that targets HER2 (human epidermal growth factor receptor 2 ). In HER2-positive breast cancer, overexpression of the HER2 protein promotes the growth and spread of cancer cells. Tucatinib inhibits the proliferation and spread of cancer cells by inhibiting the kinase activity of HER2 and blocking its downstream signaling.

Multiple clinical trials, especially the pivotal HER2CLIMB trial (NCT02614794), have provided strong evidence for the efficacy of tucatinib in HER2-positive breast cancer brain metastases. The trial showed that the combination of tucatinib and capecitabine significantly prolonged overall survival (OS) and progression-free survival (PFS) compared with trastuzumab and capecitabine alone.

In theHER2CLIMB trial, for patients with HER2-positive advanced breast cancer combined with brain metastases, tucatinib combined with trastuzumab and carbo Median OS was 21.6 months with petabine compared with 12.5 months in the control group. This result shows that tucatinib significantly reduces the patient's risk of death and prolongs the patient's survival time.

A distinctive feature of tucatinib is its high brain activity. This means that it can penetrate the blood-brain barrier and effectively inhibit the growth of tumor cells in the brain. This is particularly important for the treatment of patients with brain metastases from HER2-positive breast cancer, because brain metastases are one of the common complications in such patients and are difficult to treat.

Clinical trial data show that when treating patients with brain metastases, tucatinib not only prolongs the patient's OS and PFS, but also significantly improves intracranial progression-free survival (CNS-PFS). This shows that tucatinib can effectively control the growth and spread of tumors in the brain, thereby improving patients' quality of life and prognosis.

Although tucatinib is highly effective in the treatment of HER2 positive breast cancer brain metastases, its safety and tolerability are also the focus of attention of patients and doctors. Clinical trial data shows that the side effects of tucatinib mainly include diarrhea, redness, pain, swelling or rash on the palms or soles of the feet, blisters, oral ulcers, decreased appetite, abdominal pain, nausea, fatigue, increased levels of liver function test indicators, vomiting, headache, anemia, rash, etc. However, most patients are able to tolerate these side effects and experience symptom relief with appropriate dosage adjustments and management.

References:

https://www.cancer.gov/news-events/cancer-currents-blog/2020/tucatinib-trastuzumab-deruxtecan-her2-positive-metastatic-breast-cancer